Notable ETF Movers of the Day 11/12: (IBB) Higher; (XLU) (ITB) Lower
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Gilead (GILD) Announced Interim Phase 2 Data on Hepatitis Drugs
November 12, 2012 7:29 AM ESTGilead Sciences (Nasdaq: GILD) announced interim data from the ongoing Phase 2 ELECTRON study examining a 12-week course of therapy with the investigational nucleotide sofosbuvir (formerly referred to as GS-7977), the NS5A inhibitor GS-5885 and ribavirin in patients with genotype 1 chronic hepatitis C virus (HCV) infection. Among treatment-naïve patients receiving this combination, 100 percent (n=25/25) remained HCV RNA undetectable four weeks after completing therapy (SVR4). These data will be presented on Tuesday, November 13th at the 63rd annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2012) in Boston.... More
Beazer Homes Usa, Inc. (BZH) Misses Q3 EPS Views; New Orders Up 10.3%
November 12, 2012 6:31 AM ESTBeazer Homes Usa, Inc. (NYSE: BZH) reported Q3 EPS of ($2.57), $1.35 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $370.93 million versus the consensus estimate of $331.22 million.
New home orders up 10.3 percent to 1,110, cancellation rate down 310 bps to 31.1 percent, and... More
Celgene (CELG) Reports ABRAXANE Phase III Met Primary Endpoint in Adv. Pancreatic Cancer
November 9, 2012 5:02 PM ESTCelgene International Sà rl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III study of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically... More
Southern Co. (SO) Misses Q3 EPS by 3c
November 5, 2012 7:31 AM ESTSouthern Co. (NYSE: SO) reported Q3 EPS of $1.11, $0.03 worse than the analyst estimate of $1.14. Revenue for the quarter came in at $5.05 billion versus the consensus estimate of $5.98 billion.
For earnings history and earnings-related data on Southern Co. (SO) click here.... More
